No Data
Even With A 26% Surge, Cautious Investors Are Not Rewarding Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Performance Completely
Private Companies Among Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Largest Stockholders and Were Hit After Last Week's 5.4% Price Drop
Lushang Freda Pharmaceutical (600223.SH): Introducing the first AI digital spokesperson Cormier, reinforcing the concept of rejuvenating Ke Mei with technology.
Gelonghui November 21st, lushang freda pharmaceutical (600223.SH) stated on the investor interaction platform that lushang freda has always been exploring the development path of "technology beauty skin", taking the release of the Kemi brand as an opportunity to launch the first AI digital spokesperson Cormier, strengthening the concept of rejuvenating Kemi with "technology beauty sculpting".
Lushang Freda Pharmaceutical (600223.SH): Promoting cooperation with high-quality industry anchors and integrating special resources.
Gelonghui November 21st | Lushang Freda (600223.SH) stated on the investor interactive platform that the company has carried out a series of deployments around expanding through platforms like Douyin, optimizing product structure, innovating service mechanisms, strengthening full industry chain synergy, while enhancing the refinement level of self-broadcasting, promoting cooperation with industry's high-quality anchors and integrating special resources.
Solid Earnings May Not Tell The Whole Story For Lushang Freda PharmaceuticalLtd (SHSE:600223)
Freda: Report of Lushang Freda Pharmaceutical Co., Ltd. for the third quarter of 2024
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157%
No Data
